UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of April 2020
Commission File Number: 001-37993
OBSEVA SA
(Translation of registrant’s name into English)
Chemin des Aulx, 12
1228 Plan-les-Ouates
Geneva, Switzerland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On April 6, 2020, ObsEva SA announced the nomination of Fabien de Ladonchamps, Vice President Corporate Affairs & Finance, as interim Chief Financial Officer and member of the Executive Committee, following the resignation of Tim Adams as Chief Financial Officer, effective close of business April 10, 2020.
A copy of the press release announcing Mr. de Ladonchamps nomination and Mr. Adams resignation is filed with this Report on Form 6-K as Exhibit 99.1 and is incorporated herein by reference.
INCORPORATION BY REFERENCE
This Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3, as amended (No. 333-233069, 333-222820 and 333-221462) of ObsEva SA (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
Exhibit No. |
|
Description |
99.1 |
|
|
|
|
|
|
|
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
ObsEva SA
|
||||
|
|
|
|
|||||
Date: April 6, 2020 |
|
|
|
By: |
|
/s/ Ernest Loumaye |
||
|
|
|
|
|
|
Name |
|
Ernest Loumaye |
|
|
|
|
|
|
Title: |
|
Chief Executive Officer |
Exhibit 99.1
ObsEva SA Announces New Interim Chief Financial Officer
Geneva, Switzerland and Boston, MA – April 6, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced the nomination of Fabien de Ladonchamps, Vice President Corporate Affairs & Finance, as interim Chief Financial Officer and member of the Executive Committee, following the resignation of Tim Adams, effective close of business April 10, 2020. Tim Adams has served as CFO of ObsEva since January 2017 and is departing the Company to pursue a new opportunity.
“On behalf of the Board of Directors and Executive team, I would like to thank Tim for his contributions to the Company and leadership during his tenure at ObsEva. We would also like to thank Fabien for assuming this extended responsibility and his willingness to lead our financial operations. Fabien joined ObsEva in 2013 as a senior finance executive and has been involved in all aspects of the Company’s operations. I wish both continued success in their new positions,” said Ernest Loumaye, MD, PhD, CEO and Co-Founder of ObsEva.
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving ET outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
For further information, please contact:
CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact
Mario Corso
Senior Director, Investor Relations
mario.corso@obseva.com
+1 857 972 9347 Office
+1 781 366 5726 Mobile